First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis

May 28, 2024 Posters & Publications

Click Here to View...

Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers

May 28, 2024 Posters & Publications

Click Here to View...

Temporal Changes in the Renal Cytokine Profile in Response to AA Amyloidosis Induce Macrophage Infiltration Enabling Host-Mediated Targeting of Therapeutic Chimeric Antigen Receptor Macrophages (CARM)

May 27, 2024 Posters & Publications

Click Here to View...

Characterization of the Peptide-Antibody Fusion, AT-02- Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis

May 27, 2024 Posters & Publications

Click Here to View...

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Oct 2, 2023 Press Releases

PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs. AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent...